LENZ Therapeutics Q3 2026 Earnings Date & Estimates

LENZ Therapeutics (NASDAQ:LENZ) is a biopharmaceutical company focused on developing and commercializing pharmaceutical therapies for presbyopia, the age-related loss of near vision. The company’s approach is designed to improve near visual acuity by using aceclidine, a miotic agent intended to create a pinhole effect that can increase depth of focus while preserving distance vision.

LENZ’s lead product candidate, VIZZ, is an aceclidine hydrochloride ophthalmic solution developed as a once-daily prescription eye drop for adults with presbyopia. The company has evaluated VIZZ in late-stage clinical studies and has focused its development and regulatory efforts primarily on the U.S. ophthalmic market. LENZ’s pipeline has also included additional aceclidine-based and combination formulations intended to address near-vision impairment.

LENZ Therapeutics was established to advance topical ophthalmic treatments that could offer an alternative to reading glasses, contact lenses, or surgical procedures for people with presbyopia. The company is headquartered in San Diego, California, and is led by Chief Executive Officer Eef Schimmelpennink. Its activities have centered on clinical development, regulatory submissions, and preparation for potential commercialization of its presbyopia treatment portfolio.